Resmed (RMD) Depreciation & Amortization (CF) (2009 - 2026)

Resmed's Depreciation & Amortization (CF) history runs 18 years deep, the most recent figure standing at $59.0 million for Q1 2026.

• Quarterly Depreciation & Amortization (CF) rose 35.05% year-over-year to $59.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $220.2 million (up 23.34% YoY) and the FY2025 annual result came in at $198.5 million, up 12.21% from the prior year.
• Depreciation & Amortization (CF) was $59.0 million for Q1 2026 at Resmed, up from $49.9 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $63.6 million in Q2 2025 and bottomed at $36.3 million in Q3 2022.
• A 5-year average of $45.7 million and a median of $44.7 million in 2024 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) retreated 7.41% — and 2025, when it surged 45.68%.
• Resmed's Depreciation & Amortization (CF) stood at $37.8 million in 2022, then increased by 18.58% to $44.8 million in 2023, then rose by 3.7% to $46.4 million in 2024, then advanced by 7.42% to $49.9 million in 2025, then grew by 18.23% to $59.0 million in 2026.
• Business Quant data shows RMD's Depreciation & Amortization (CF) at $59.0 million in Q1 2026, $49.9 million in Q4 2025, and $47.7 million in Q3 2025.